Finance

Lists
Why is LXEO down 3.11%?
Dive Deeper
LXEO:NASDAQ
Lexeo Therapeutics Inc
$2.80
-3.11%
(-0.090) 1D
$2.80
0.00% (0.00)
After hours
Closed: Oct 23, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LXEO...
Open
$2.87
High
$2.96
Low
$2.73
Mkt. cap
229.86M
Avg. vol.
1.80M
Volume
619.38K
52-wk high
$10.99
52-wk low
$2.55
EPS
-$1.16
Shares outstanding
82.09M
No. of employees
63
Open
$2.87
High
$2.96
Low
$2.73
Mkt. cap
229.86M
Avg. vol.
1.80M
Volume
619.38K
52-wk high
$10.99
52-wk low
$2.55
EPS
-$1.16
Shares outstanding
82.09M
No. of employees
63
News stories
From web sources and news partners
About Lexeo Therapeutics Inc
CEO-
Employees63
Founded2017
Headquarters-
SectorBiotechnology
Websitelexeotx.com
Analyst ratings
Based on 5 analysts giving stock ratings to LXEO in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for LXEO in the last 3 months.
Highest
Current $2.80
$23.00 (+721.43%)
Average
$19.00 (+578.57%)
Lowest
$15.00 (+435.71%)
Analyst
Recommendation
Action
Price target
Projected
Date
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
$23.00
+721.4%
10/21/2026
Paul Matteis
Stifel Nicolaus
Buy
Reiterated
$17.00
+507.1%
10/05/2026
Unknown Analyst
Leerink Partners
Buy
Reiterated
$15.00
+435.7%
09/23/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
$20.00
+614.3%
09/23/2026
Luca Issi
RBC Capital
Buy
Maintained
$20.00
+614.3%
08/12/2026
Tessa Romero
J.P. Morgan
Buy
Maintained
$9.00
+221.4%
06/25/2026
Unknown Analyst
Stifel Nicolaus
Buy
Maintained
$17.00
+507.1%
05/12/2026
Geulah Livshits
Chardan Capital
Buy
Reiterated
$17.00
+507.1%
05/11/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$10.00
+257.1%
01/13/2026
Christopher Raymond
Raymond James
Buy
Maintained
$25.00
+792.9%
01/13/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
15.70M
16.21M
15.70M
19.03M
Cost of revenue
15.70M
16.21M
15.70M
19.03M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.95M
6.91M
6.63M
8.99M
Operating expense
5.95M
6.91M
6.63M
8.99M
Total operating expenses
21.65M
23.12M
22.33M
28.02M
Operating income
-21.65M
-23.12M
-22.33M
-28.02M
Other non operating income
-9.00K
9.00K
-1.00K
-6.00K
EBT including unusual items
-20.28M
-20.92M
-20.20M
-25.87M
EBT excluding unusual items
-20.22M
-20.91M
-20.24M
-25.85M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-20.28M
-20.92M
-20.20M
-25.87M
Net profit margin
-
-
-
-
Earnings per share
-0.33
-0.27
-0.25
-0.30
Interest and investment income
1.46M
2.21M
2.11M
2.19M
Interest expense
-22.00K
-20.00K
-17.00K
-14.00K
Net interest expenses
1.43M
2.19M
2.10M
2.18M
Depreciation and amortization charges
-
-
-
-
EBITDA
-21.50M
-22.96M
-22.18M
-27.87M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps